212 related articles for article (PubMed ID: 11311125)
41. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
42. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
43. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes.
Nykjaer A; Conese M; Christensen EI; Olson D; Cremona O; Gliemann J; Blasi F
EMBO J; 1997 May; 16(10):2610-20. PubMed ID: 9184208
[TBL] [Abstract][Full Text] [Related]
44. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
[TBL] [Abstract][Full Text] [Related]
45. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
46. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
[TBL] [Abstract][Full Text] [Related]
47. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
48. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
49. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
Mazzieri R; D'Alessio S; Kenmoe RK; Ossowski L; Blasi F
Mol Biol Cell; 2006 Jan; 17(1):367-78. PubMed ID: 16267271
[TBL] [Abstract][Full Text] [Related]
50. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
51. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
52. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
53. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
54. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils.
Plesner T; Ploug M; Ellis V; Rønne E; Høyer-Hansen G; Wittrup M; Pedersen TL; Tscherning T; Danø K; Hansen NE
Blood; 1994 Feb; 83(3):808-15. PubMed ID: 8298141
[TBL] [Abstract][Full Text] [Related]
55. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
[TBL] [Abstract][Full Text] [Related]
56. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
57. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
58. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.
Cubellis MV; Nolli ML; Cassani G; Blasi F
J Biol Chem; 1986 Dec; 261(34):15819-22. PubMed ID: 3023326
[TBL] [Abstract][Full Text] [Related]
59. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
60. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
